Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Bérangère Narciso"'
Autor:
Marine Gross-Goupil, Sophie Tartas, Sabrina Falkowski, Reza Elaidi, Alain Ravaud, Yann-Alexandre Vano, Sylvain Ladoire, Eric Voog, Jean-Christophe Eymard, Slimane Dermeche, Bérangère Narciso, Gabriel G. Malouf, Christophe Sajous
Publikováno v:
Cancers
Cancers, Vol 13, Iss 5548, p 5548 (2021)
Cancers, Vol 13, Iss 5548, p 5548 (2021)
Simple Summary First-line treatment options for metastatic clear cell renal cell carcinoma have significantly increased. The current recommended therapeutic strategy is based on a combination, but monotherapy remains an alternative. However, the choi
Autor:
Bernard Escudier, F. Schlürmann, Y. Vano, P. Bigot, A. Thiery-Vuillemin, S. Néré, C. Quentric, Bérangère Narciso, L. Albiges, Philippe Barthélémy
Publikováno v:
European Urology Open Science. 33:S321
Autor:
Antoine Thiery-Vuillemin, M. Chehimi, C. Quentric, Bérangère Narciso, J. Barthomeuf, Pierre Bigot, F. Schlürmann, L. Albiges, F. Calcagno, J.-C. Eymard, Philippe Barthélémy, Bernard Escudier, Yann-Alexandre Vano
Publikováno v:
Annals of Oncology. 32:S697
Autor:
Sylvie Negrier, Bernard Escudier, Sylvain Ladoire, Stéphane Oudard, Florian Bardet, Laurence Albiges, Christine Chevreau, Marine Gross-Goupil, Gwenaelle Gravis, Cécile Dalban, Jean Marc Ferrero, Brigitte Laguerre, Antoine Thiery-Vuillemin, Lionnel Geoffrois, Florence Tantot, Bérangère Narciso, Hakim Mahammedi, Philippe Barthélémy
Publikováno v:
Journal of Clinical Oncology. 39:e16566-e16566
e16566 Background: Nivolumab monotherapy (N) is a standard of care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of antiangiogenic therapies. IMDC criteria is the established prognostic model in anyline of systemi
Autor:
Emmanuelle Mercier, A. Legras, Bérangère Narciso, Denis Garot, Pierre-François Dequin, Dominique Perrotin, Gilles Rival
Publikováno v:
La Presse Médicale. 35:980-982
Resume Introduction L’instillation intravesicale de bacille de Calmette et Guerin (BCG), traitement de reference des tumeurs superficielles de vessie, peut s’accompagner d’effets indesirables dans moins de 5% des cas. Les effets secondaires les
Autor:
Gilles, Rival, Denis, Garot, Emmanuelle, Mercier, Bérangère, Narciso, Annick, Legras, Dominique, Perrotin, Pierre-François, Dequin
Publikováno v:
Presse medicale (Paris, France : 1983). 35(6 Pt 1)
Intravesical bacillus Calmette-Guerin (BCG) therapy, recommended for superficial bladder tumors, triggers side effects in fewer than 5% of patients. The most severe side effects, however, are septic shock and acute respiratory failure.A 70-year-old m
Autor:
Laurence Brugières, Muriel Rogasik, Perrine Marec-Berard, Helène Cornille, Magali Girodet, Natacha Entz-Werle, Mathilde Penel-Page, Nadège Corradini, Julien Domont, Jean-Yves Blay, Bérangère Narciso, Antoine Thyss, Sophie Piperno-Neumann, Julie Larcade, Cyril Lervat, Laure Bouclier, Jean-Claude Gentet, Hélène Pacquement, Isabelle Ray-Coquard, Jacques-Olivier Bay, Loic Chaigneau
Publikováno v:
BMC Cancer
Background The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with osteosarcoma registered within the French Sarcoma Group – Bone Tumor Study Group (GSF-GETO) national registry. Methods All patients